All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Bookmark this article
On 23 July 2019, abexinostat was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use as a fourth-line monotherapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).1 Abexinostat is an oral small molecule inhibitor of histone deacetylase (HDAC) that alters the transcription of oncogenes and tumor suppressor genes, leading to inhibition of cancer growth.
The Fast Track designation was based on the positive results from a multicenter phase II clinical trial FORERUNNER (NCT03600441), evaluating the efficacy and safety of abexinostat as a single agent in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). The trial2 demonstrated an overall response rate (ORR) of 56% in patients with FL, 40% in T-cell lymphoma, and 31% in diffuse large B-cell lymphoma (DLBCL). Adverse events (grade ≥3) were reported in 88% of patients with NHL, with thrombocytopenia (80%), neutropenia (27%), and anemia (12%) the most frequently reported.
Abexinostat in combination with pazopanib was previously granted the FDA’s Fast Track designation as a first or second-line treatment for patients with renal cell carcinoma.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox